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there was a signiﬁcant positive correlation between delta eGFR
and ribavirin serum concentration, and the ribavirin serum con-
centration at week 1 was negatively correlated with the Hb levels
from week 2 to week 8 [5]. Although the exact mechanisms are
still not completely understood, all together, these data suggest
that telaprevir and boceprevir can impair renal function early
in the course of triple therapy for hepatitis C infection, and that
this impairment can lead to ribavirin accumulation and can
explain, at least in part, the higher rates of anemia observed in
triple vs. double therapy. On the base of these evidences, we think
that renal function should be assessed not only before, as already
recommended, but also early after the beginning of triple therapy
(1–2 weeks), that those patients experiencing a decline of eGFR
should be strictly monitored, and that an early reduction of
ribavirin dose should be strongly considered at least in patients
experiencing a reduction of eGFR to <60 ml/min.
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OpenReply to: ‘‘Renal impairment and anemia during triple therapy’’To the Editor:
We appreciate the comment by Vespasiani-Gentilucci et al. about
renal impairment and anemia during hepatitis C treatment with
protease inhibitors. We agree with the authors that renal impair-
ment is a growing concern in these patients, although the preva-
lence of estimated glomerular ﬁltration rate (eGFR) <60 ml/min
does not seem to be signiﬁcantly high with these drugs (6.6%
with boceprevir and 4.7% with telaprevir [1]). Additionally to pro-
tease inhibitors, older age, arterial hypertension, high baseline
serum creatinine as well as type 2 diabetes mellitus were found
to be associated with anemia [2]. Probably, the link between
these factors and anemia is the appearance of renal impairment
[3]. Indeed, the mechanisms involved in renal impairment with
protease inhibitors remain poorly understood. Signiﬁcant inhibi-
tion of some human renal drug transporters that could inﬂuence
ribavirin serum concentration has been described with telaprevir
[4]. This has been correlated with delta eGFR [5]. Telaprevir
though has shown an acceptable tolerability in haemodialyzed
patients who were listed for kidney transplantation, managing
successfully anemia with erythropoietin and ribavirin dosections [6]. On the other hand, mean boceprevir concentration
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 access under CC BY-NC-ND license.was comparable in patients with end-stage renal disease and in
healthy subjects [7]. In conclusion, there is a mild risk of renal
insufﬁciency stage 3 with protease inhibitors that could be
responsible, at least in part, of the anemia that develops during
triple therapy. Thus, renal function should be closely monitored
to anticipate the appearance of anemia.
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Evidence recommending antiviral therapy in hepatitis C
To the Editor:
Recently, Dr. Van der Meer and colleagues [1] discussed our sys-
tematic review of trials comparing interferon monotherapy to no
therapy for retreating individuals infected with hepatitis C virus
who had not achieved a sustained virological response (SVR)
from previous antiviral therapy [2]. Our review made several
observations: (1) retreatment with interferon monotherapy pro-
vided no relevant clinical beneﬁt; (2) while there was a statisti-
cally signiﬁcant reduction in non-fatal variceal bleeding, the
number needed to treat (NNT) was so high (NNT = 67) that the
treatment is economically unfeasible; (3) when only the low risk
of bias trials were considered, interferon treatment increased all-
cause mortality; (4) the recipients of interferon had more adverse
events; and (5) the commonly used surrogate outcome of SVR
occurred signiﬁcantly more often in the treated group.
Since interferon treatment increased SVRs without improving
clinical outcomes, the SVR was not a valid surrogate outcome in
this scenario. As such, SVR cannot be universally considered as
valid for purposes of clinical practice. We believe that, before it
can be considered a trustworthy surrogate outcome in other sce-
narios, it must be validated in those scenarios, or at least in
enough other scenarios that the single example of retreatment
of interferon monotherapy could be considered to be an outlier.
Validation of a surrogate outcome is a two-step process [3].
First, there has to be a strong and consistent association between
the surrogate outcome and the clinical one. However, association
alone is not adequate to establish validation. It also has to be
shown that improving the surrogate outcome also similarly
improves the clinical one; in other words, a treatment-related
difference between the study groups in the surrogate outcome
should be associated with a proportionate treatment-related dif-
ference in the clinical outcome. This latter step can only be dem-
onstrated in randomized clinical trial (RCTs). Most RCTs assessing
hepatitis C antiviral therapy do not provide clinical outcomes,
presumably because these outcomes require years to pass before
they begin to appear. Thus, there are limited data available to
assess the validity of the SVR. Of note, several other Cochrane
reviews also found scenarios in which an improved SVR did not
translate into a meaningful beneﬁcial clinical outcome These
included comparing interferon with or without ribavirin [4],
using ribavirin alone [5], and employing interferon in treat-
ment-naïve patients [6]. Dr. van der Meer and his colleagues cited
two of these [4,6], but only noted that the improvement in SVR
was accompanied by improvement in liver histology (another
surrogate). Not mentioned by van der Meer et al., adding ribavirin
to interferon resulted in a minimal but statistically signiﬁcant
reduction in the combined endpoint of death and hepatic mor-
bidity (0.28% reduced to 0.12%), but the NNT was 625 (compared
to an NNT of 4 for achieving an SVR) [4].
Van der Meer et al. appeared to be most concerned with our
statement that the presence of treatment harm and the failed val-
idation of SVRs ‘‘should caution us to stop advocating antiviral
interventions of any kind until we have evidence of clinical
efﬁcacy and cost-effectiveness’’ [2]. To support their argument
that SVR is a good outcome to assess antiviral therapy, they cite
a number of lines of evidence that demonstrate the association
between SVR and good outcomes. We agree with them that the
SVR is a good prognostic sign. However, the key issue is that
the SVR has not been validated as a surrogate outcome. In other
words, there are no RCTs that have shown that a treatment that
increases the number of SVRs equates with improved clinical out-
comes. Van der Meer et al. agree that this is the case.
We and van der Meer et al. also agree that most infected
patients will not develop decompensated liver disease or hepato-
cellular carcinoma and that the prognostic factors identifying
patients who are likely to achieve an SVR are also factors that
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